Reported Earnings • 14h
Full year 2026 earnings released: EPS: ₹1.21 (vs ₹0.09 in FY 2025) Full year 2026 results: EPS: ₹1.21 (up from ₹0.09 in FY 2025). Revenue: ₹1.32b (up 331% from FY 2025). Net income: ₹25.6m (up ₹24.7m from FY 2025). Profit margin: 1.9% (up from 0.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth. Announcement • May 25
Novelix Pharmaceuticals Limited to Report Q4, 2026 Results on May 29, 2026 Novelix Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 29, 2026 Announcement • Mar 30
Novelix Pharmaceuticals Limited Announces Resignation of Jivamohan Divakar Valluri as Non-Executive Director and Changes in Committee Composition, Effective March 30, 2026 Novelix Pharmaceuticals Limited announced that Mr. Jivamohan Divakar Valluri has expressed his intention to resign as a Non-Executive Non-Independent Director of the Company with effect from the close of business hours on March 30, 2026, due to pre-occupation and other personal commitments. Consequent to his resignation, he shall also step down from his positions as a member of the Audit Committee, Nomination & Remuneration Committee, and as Chairperson of the Stakeholders’ Relationship Committee of the Company. The Board of Directors of the Company in its meeting held on March 30, 2026, considered and approved the resignation of Mr. Jivamohan Divakar Valluri (DIN: 09218013) as Non-Executive Director of the Company with effect from closure of business hours on March 30, 2026.